<article title='Cholesterol'><paragraph><template><target>Use dmy dates</target><arg name="date">July 2013</arg></template><template><target>chembox</target><arg name="Watchedfields"><space/>changed
</arg><arg name="verifiedrevid"><space/>477165736
</arg><arg name="ImageFile"><space/>Cholesterol.svg
</arg><arg name="ImageSize"><space/>240
</arg><arg name="ImageAlt"><space/>Chemical structure of cholesterol
</arg><arg name="ImageFile2"><space/>Cholesterol molecule ball.png
</arg><arg name="ImageSize2"><space/>260
</arg><arg name="ImageAlt2"><space/>Ball-and-stick model of cholesterol
</arg><arg name="ImageFile3"><space/>Sample of Cholesterol.jpg
</arg><arg name="ImageSize3"><space/>200
</arg><arg name="ImageAlt3"><space/>Sample of Cholesterol
</arg><arg name="IUPACName">(3β)-cholest-5-en-3-ol
</arg><arg name="SystematicName">2,15-dimethyl-14-(1,5-dimethylhexyl)tetracyclo[8.7.0.0<sup>2,7</sup>.0<sup>11,15</sup>]heptadec-7-en-5-ol
</arg><arg name="OtherNames">(10''R'',13''R'')-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1''H''-cyclopenta[''a'']phenanthren-3-ol, Cholesterin, Cholesteryl alcohol<space/><ref name</arg><arg name="Section1">{{Chembox Identifiers
| IUPHAR_ligand<space/></arg><arg name="Section2">{{Chembox Properties
| Formula<space/></arg><arg name="Section7">{{Chembox Hazards
| MainHazards<space/></arg></template><link><target>Image:Adamantinomatous craniopharyngioma.jpg</target><part>thumb</part><part>200px</part><part>right</part><part>Microscopic appearance of cholesterol crystals in water. Photo taken under<space/><link><target>polarized light</target></link>.</part></link></paragraph><paragraph><bold>Cholesterol</bold>, from the<space/><link><target>Ancient Greek</target></link><space/><italics>chole-</italics><space/>(<link><target>bile</target></link>) and<space/><italics>stereos</italics><space/>(solid) followed by the<space/><link><target>chemical</target></link><space/><link><target>suffix</target></link><space/><italics>-ol</italics><space/>for an alcohol, is an<space/><link><target>organic compound</target><part>organic</part></link><space/><link><target>molecule</target></link>. It is a<space/><link><target>sterol</target></link><space/>(or<space/><link><target>chemical modification</target><part>modified</part></link><space/><link><target>steroid</target></link>),<extension extension_name='ref'><template><target>MeshName</target><arg>Cholesterol</arg><arg>2013</arg></template></extension><space/>a<space/><link><target>lipid</target></link><space/>molecule and is<space/><link><target>biosynthesis</target><part>biosynthesized</part></link><space/>by all animal cells because it is an essential structural component of all animal (not plant or bacterial)<space/><link><target>cell membrane</target><trail>s</trail></link><space/>that is required to maintain both membrane structural integrity and<space/><link><target>membrane fluidity</target><part>fluidity</part></link>. Cholesterol enables animal cells to not need a cell wall (like plants and bacteria) to protect membrane integrity/cell-viability, thus are able to change shape and move about (unlike bacteria and plant cells which are restricted by their cell walls).</paragraph><paragraph>In addition to its importance within cells, cholesterol also serves as a precursor for the biosynthesis of<space/><link><target>steroid hormone</target><trail>s</trail></link>,<space/><link><target>bile acid</target><trail>s</trail></link>, and<space/><link><target>vitamin D</target></link>.<extension extension_name='ref' name="pmid22217824"><template><target>cite journal</target><arg name="vauthors"><space/>Hanukoglu I<space/></arg><arg name="title"><space/>Steroidogenic enzymes: structure, function, and role in regulation of steroid hormone biosynthesis.<space/></arg><arg name="journal"><space/>J Steroid Biochem Mol Biol<space/></arg><arg name="volume"><space/>43<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>779–804<space/></arg><arg name="date"><space/>Dec 1992<space/></arg><arg name="pmid"><space/>22217824<space/></arg><arg name="doi"><space/>10.1016/0960-0760(92)90307-5<space/></arg></template></extension><space/>Cholesterol is the principal<space/><link><target>sterol</target></link><space/>synthesized by animals. All kinds of cells in animals can produce it. In<space/><link><target>vertebrate</target><trail>s</trail></link><space/>the<space/><link><target>liver</target><part>hepatic</part></link><space/>cells typically produce greater amounts than other cells. It is almost completely absent among<space/><link><target>prokaryote</target><trail>s</trail></link><space/>(<link><target>bacteria</target></link><space/>and<space/><link><target>archaea</target></link>), although there are some exceptions such as<space/><link><target>Mycoplasma</target></link>, which require cholesterol for growth.<extension extension_name='ref'><template><target>cite journal</target><arg name="vauthors"><space/>Razin S, Tully JG<space/></arg><arg name="title"><space/>Cholesterol Requirement of Mycoplasmas<space/></arg><arg name="journal"><space/>Journal of Bacteriology<space/></arg><arg name="volume"><space/>102<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>306–310<space/></arg><arg name="date"><space/>May 1970<space/></arg><arg name="pmid"><space/>4911537<space/></arg><arg name="pmc"><space/>247552<space/></arg></template></extension></paragraph><paragraph><link><target>Franois Poulletier de la Salle</target></link><space/>first identified cholesterol in solid form in<space/><link><target>gallstone</target><trail>s</trail></link><space/>in 1769. However, it was not until 1815 that chemist<space/><link><target>Michel Eugne Chevreul</target></link><space/>named the compound &quot;cholesterine&quot;.<extension extension_name='ref'>Chevreul (1816) &quot;Recherches chimiques sur les corps gras, et particulirement sur leurs combinaisons avec les alcalis. Sixime mmoire. Examen des graisses d'homme, de mouton, de boeuf, de jaguar et d'oie&quot; (Chemical researches on fatty substances, and particularly on their combinations o filippos ine kapios with alkalis. Sixth memoir. Study of human, sheep, beef, jaguar and goose fat),<space/><italics>Annales de Chimie et de Physique</italics>,<space/><bold>2</bold><space/>: 339-372. From<space/><link type='external' href='http://books.google.com/books?id=DHCz1nhhYL8C&amp;amp;pg=PA346#v=onepage&amp;amp;q&amp;amp;f=false'>page 346</link><space/>: &quot;Je nommerai<space/><italics>cholesterine</italics>, de , bile, et , solide, la substance cristallise des calculs biliares humains, ... &quot; (I will name<space/><italics>cholesterine</italics><space/>from (bile) and (solid) the crystalized substance from human gallstones ... )</extension><extension extension_name='ref' name="pmid9478044"><template><target>cite journal</target><arg name="vauthors"><space/>Olson RE<space/></arg><arg name="title"><space/>Discovery of the lipoproteins, their role in fat transport and their significance as risk factors<space/></arg><arg name="journal"><space/>J. Nutr.<space/></arg><arg name="volume"><space/>128<space/></arg><arg name="issue"><space/>2 Suppl<space/></arg><arg name="pages"><space/>439S–443S<space/></arg><arg name="date"><space/>February 1998<space/></arg><arg name="pmid"><space/>9478044<space/></arg><arg name="doi"><space/></arg><arg name="url"><space/>http://jn.nutrition.org/cgi/pmidlookup?view</arg></template></extension></paragraph><heading level='2'>Physiology</heading><paragraph>Since cholesterol is essential for all animal life, each cell synthesizes it through a complex process beginning with<space/><link><target>mevalonate pathway</target></link><space/>and ending with the 19 step conversion of<space/><link><target>lanosterol</target></link><space/>to cholesterol. Particularly high levels of fats (including cholesterol) in the blood circulation, depending on how they are transported within<space/><link><target>lipoprotein</target><trail>s</trail></link>, are strongly associated with the progression of<space/><link><target>atherosclerosis</target></link><space/>(arteriosclerotic vascular disease).</paragraph><paragraph>A human male weighing 68&amp;nbsp;kg (150&amp;nbsp;lb) normally synthesises about 1 g (1,000&amp;nbsp;mg) per day, and his body contains about 35 g, mostly contained within the cell membranes. Typical cholesterol dietary intake for a man in the United States is 307&amp;nbsp;mg, which is above the upper limit recommended by the Dietary Guidelines Advisory Committee.<extension extension_name='ref' name="cdc-calories"><template><target>cite web</target><arg name="last"><space/></arg><arg name="first"><space/></arg><arg name="title"><space/>National Health and Nutrition Examination Survey<space/></arg><arg name="publisher"><space/>United States Center for Disease Control<space/></arg><arg name="url"><space/>http://www.cdc.gov/nchs/data/nhanes/databriefs/calories.pdf<space/></arg><arg name="format">PDF<space/></arg><arg name="accessdate"><space/>2012-01-28</arg></template></extension></paragraph><paragraph>Most ingested cholesterol is<space/><link><target>esterified</target></link>, and esterified cholesterol is poorly absorbed. The body also compensates for any absorption of additional cholesterol by reducing cholesterol synthesis.<extension extension_name='ref'><template><target>cite journal</target><arg name="vauthors"><space/>Lecerf JM, de Lorgeril M<space/></arg><arg name="title"><space/>Dietary cholesterol: from physiology to cardiovascular risk<space/></arg><arg name="journal"><space/>Br J Nutr<space/></arg><arg name="volume"><space/>106<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>6–14<space/></arg><arg name="year"><space/>2011<space/></arg><arg name="pmid"><space/>21385506<space/></arg><arg name="doi"><space/>10.1017/S0007114511000237<space/></arg></template></extension><space/>For these reasons, seven to ten hours after ingestion, cholesterol will show little, if any, effect on total body cholesterol content or concentrations of cholesterol in the blood. However, during the first seven hours after ingestion of cholesterol, the levels significantly increase.<extension extension_name='ref'><template><target>cite journal</target><arg name="vauthors"><space/>Dubois C, Armand M, Mekki N, Portugal H, Pauli AM, Bernard PM, Lafont H, Lairon D<space/></arg><arg name="title"><space/>Effects of increasing amounts of dietary cholesterol on postprandial lipemia and lipoproteins in human subjects<space/></arg><arg name="journal"><space/>Journal of LIPID Research<space/></arg><arg name="volume"><space/>35<space/></arg><arg name="issue"><space/>1994<space/></arg><arg name="pages"><space/>1993–2007<space/></arg><arg name="date"><space/>1994<space/></arg><arg name="pmid"><space/>7868978<space/></arg></template></extension></paragraph><paragraph>Cholesterol is recycled. The liver excretes it in a non-esterified form (via bile) into the digestive tract. Typically, about 50% of the excreted cholesterol is reabsorbed by the small bowel back into the bloodstream.</paragraph><paragraph>Plants make cholesterol in very small amounts.<extension extension_name='ref' name="Plant cholesterol"><template><target>cite journal</target><arg name="journal">Journal of Chemical Education</arg><arg name="last1">Behrman</arg><arg name="first1">E. J.</arg><arg name="last2">Gopalan</arg><arg name="first2">Venkat</arg><arg name="url">http://chemistry.osu.edu/~gopalan.5/file/7B.PDF</arg><arg name="title">Cholesterol and Plants</arg><arg name="editor">William M. Scovell</arg><arg name="volume">82</arg><arg name="number">12</arg><arg name="year">2005</arg><arg name="pages">1791</arg><arg name="doi">10.1021/ed082p1791</arg><arg name="bibcode">2005JChEd..82.1791B</arg></template></extension><space/>Plants manufacture<space/><link><target>phytosterol</target><trail>s</trail></link><space/>(substances chemically similar to cholesterol produced within plants), which can compete with cholesterol for reabsorption in the intestinal tract, thus potentially reducing cholesterol reabsorption.<extension extension_name='ref' name="pmid17218830"><template><target>cite journal</target><arg name="vauthors"><space/>John S, Sorokin AV, Thompson PD<space/></arg><arg name="title"><space/>Phytosterols and vascular disease<space/></arg><arg name="journal"><space/>Curr. Opin. Lipidol.<space/></arg><arg name="volume"><space/>18<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>35–40<space/></arg><arg name="date"><space/>February 2007<space/></arg><arg name="pmid"><space/>17218830<space/></arg><arg name="doi"><space/>10.1097/MOL.0b013e328011e9e3<space/></arg></template></extension><space/>When intestinal lining cells absorb phytosterols, in place of cholesterol, they usually excrete the phytosterol molecules back into the<space/><link><target>GI tract</target></link>, an important protective mechanism.</paragraph><heading level='3'>Function</heading><paragraph>Cholesterol is required to build and maintain<space/><link><target>Cell membrane</target><part>membranes</part></link>; it modulates<space/><link><target>membrane fluidity</target></link><space/>over the range of physiological temperatures. The<space/><link><target>hydroxyl</target></link><space/>group on cholesterol interacts with the<space/><link><target>Polar molecules</target><part>polar</part></link><space/>head groups of the<space/><link><target>lipid bilayer</target><part>membrane</part></link><space/><link><target>phospholipid</target><trail>s</trail></link><space/>and<space/><link><target>sphingolipid</target><trail>s</trail></link>, while the bulky<space/><link><target>steroid</target></link><space/>and the<space/><link><target>hydrocarbon</target></link><space/>chain are embedded in the membrane, alongside the<space/><link><target>Polar molecules#Nonpolar molecules</target><part>nonpolar</part></link><space/><link><target>Fatty acid</target><part>fatty-acid chain</part></link><space/>of the other lipids. Through the interaction with the phospholipid fatty-acid chains, cholesterol increases membrane packing, which reduces membrane fluidity.<extension extension_name='ref' name="isbn1-4292-4646-4"><template><target>cite book</target><arg name="author"><space/>Sadava D, Hillis DM, Heller HC, Berenbaum MR<space/></arg><arg name="title"><space/>Life: The Science of Biology 9th Edition<space/></arg><arg name="publisher"><space/>Freeman<space/></arg><arg name="location"><space/>San Francisco<space/></arg><arg name="year"><space/>2011<space/></arg><arg name="pages"><space/>105–114<space/></arg><arg name="isbn"><space/>1-4292-4646-4<space/></arg></template></extension><space/>The structure of the tetracyclic ring of cholesterol contributes to the decreased fluidity of the cell membrane as the molecule is in a trans conformation making all but the side chain of cholesterol rigid and planar.<extension extension_name='ref' name="pmid11694269"><template><target>cite journal</target><arg name="vauthors"><space/>Ohvo-Rekilä H, Ramstedt B, Leppimäki P, Slotte JP<space/></arg><arg name="title"><space/>Cholesterol interactions with phospholipids in membranes<space/></arg><arg name="journal"><space/>Prog. Lipid Res.<space/></arg><arg name="volume"><space/>41<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>66–97<space/></arg><arg name="date"><space/>January 2002<space/></arg><arg name="pmid"><space/>11694269<space/></arg><arg name="doi"><space/>10.1016/S0163-7827(01)00020-0<space/></arg></template></extension><space/>In this structural role, cholesterol reduces the permeability of the plasma membrane to neutral solutes,<extension extension_name='ref' name="pmid1664240"><template><target>cite journal</target><arg name="vauthors"><space/>Yeagle PL<space/></arg><arg name="title"><space/>Modulation of membrane function by cholesterol<space/></arg><arg name="journal"><space/>Biochimie<space/></arg><arg name="volume"><space/>73<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>1303–10<space/></arg><arg name="date"><space/>October 1991<space/></arg><arg name="pmid"><space/>1664240<space/></arg><arg name="doi"><space/>10.1016/0300-9084(91)90093-G<space/></arg></template></extension><space/><link><target>hydrogen</target></link><space/>ions, and<space/><link><target>sodium</target></link><space/>ions.<extension extension_name='ref' name="Haines_2001"><template><target>cite journal</target><arg name="vauthors"><space/>Haines TH<space/></arg><arg name="title"><space/>Do sterols reduce proton and sodium leaks through lipid bilayers?<space/></arg><arg name="journal"><space/>Prog. Lipid Res.<space/></arg><arg name="volume"><space/>40<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>299–324<space/></arg><arg name="date"><space/>July 2001<space/></arg><arg name="pmid"><space/>11412894<space/></arg><arg name="doi"><space/>10.1016/S0163-7827(01)00009-1<space/></arg></template></extension></paragraph><paragraph>Within the cell membrane, cholesterol also functions in intracellular transport, cell signaling and nerve conduction. Cholesterol is essential for the structure and function of invaginated<space/><link><target>caveolae</target></link><space/>and<space/><link><target>clathrin</target></link>-coated pits, including caveola-dependent and clathrin-dependent<space/><link><target>endocytosis</target></link>. The role of cholesterol in such endocytosis can be investigated by using<space/><link><target>methyl beta cyclodextrin</target></link><space/>(MCD) to remove cholesterol from the plasma membrane. Recent studies show that cholesterol is also implicated in cell signaling processes, assisting in the formation of<space/><link><target>lipid raft</target><trail>s</trail></link><space/>in the<space/><link><target>plasma membrane</target></link>. Lipid raft formation brings receptor proteins in close proximity with high concentrations of second messenger molecules.<extension extension_name='ref' name="pmid10712926"><template><target>cite journal</target><arg name="vauthors"><space/>Incardona JP, Eaton S<space/></arg><arg name="title"><space/>Cholesterol in signal transduction<space/></arg><arg name="journal"><space/>Curr. Opin. Cell Biol.<space/></arg><arg name="volume"><space/>12<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>193–203<space/></arg><arg name="date"><space/>April 2000<space/></arg><arg name="pmid"><space/>10712926<space/></arg><arg name="doi"><space/>10.1016/S0955-0674(99)00076-9<space/></arg></template></extension><space/>In many neurons, a<space/><link><target>myelin</target></link><space/>sheath, rich in cholesterol, since it is derived from compacted layers of<space/><link><target>Schwann cell</target></link><space/>membrane, provides insulation for more efficient conduction of impulses.<extension extension_name='ref' name="isbn0-7817-5056-3"><template><target>cite book</target><arg name="author"><space/>Pawlina W, Ross MW<space/></arg><arg name="authorlink"><space/></arg><arg name="editor"><space/></arg><arg name="others"><space/></arg><arg name="title"><space/>Histology: a text and atlas: with correlated cell and molecular biology<space/></arg><arg name="edition"><space/></arg><arg name="publisher"><space/>Lippincott Wiliams & Wilkins<space/></arg><arg name="location"><space/>Philadelphia<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="origyear"><space/></arg><arg name="pages"><space/>230<space/></arg><arg name="quote"><space/></arg><arg name="isbn"><space/>0-7817-5056-3<space/></arg></template></extension></paragraph><paragraph>Within cells, cholesterol is the precursor molecule in several biochemical pathways. In the liver, cholesterol is converted to<space/><link><target>bile</target></link>, which is then stored in the<space/><link><target>gallbladder</target></link>. Bile contains bile salts, which solubilize fats in the digestive tract and aid in the intestinal absorption of fat molecules as well as the fat-soluble vitamins,<space/><link><target>Vitamin A</target><part>A</part></link>,<space/><link><target>Vitamin D</target><part>D</part></link>,<space/><link><target>Vitamin E</target><part>E</part></link>, and<space/><link><target>Vitamin K</target><part>K</part></link>. Cholesterol is an important precursor molecule for the synthesis of vitamin D and the<space/><link><target>steroid hormones</target></link>, including the<space/><link><target>adrenal gland</target></link><space/>hormones<space/><link><target>cortisol</target></link><space/>and<space/><link><target>aldosterone</target></link>, as well as the sex hormones<space/><link><target>progesterone</target></link>,<space/><link><target>estrogen</target><trail>s</trail></link>, and<space/><link><target>testosterone</target></link>, and their derivatives.<extension extension_name='ref' name="pmid22217824"></extension></paragraph><paragraph>Some research indicates cholesterol may act as an<space/><link><target>antioxidant</target></link>.<extension extension_name='ref' name="Smith_1991"><template><target>cite journal</target><arg name="vauthors"><space/>Smith LL<space/></arg><arg name="title"><space/>Another cholesterol hypothesis: cholesterol as antioxidant<space/></arg><arg name="journal"><space/>Free Radic. Biol. Med.<space/></arg><arg name="volume"><space/>11<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>47–61<space/></arg><arg name="year"><space/>1991<space/></arg><arg name="pmid"><space/>1937129<space/></arg><arg name="doi"><space/>10.1016/0891-5849(91)90187-8<space/></arg></template></extension></paragraph><heading level='3'>Dietary Sources</heading><paragraph><link><target>Animal fat</target><trail>s</trail></link><space/>are complex mixtures of<space/><link><target>triglyceride</target><trail>s</trail></link>, with lesser amounts of<space/><link><target>phospholipid</target><trail>s</trail></link><space/>and cholesterol. As a consequence, all foods containing animal fat contain cholesterol to varying extents.<extension extension_name='ref' name="isbn0-9531949-5-7"><template><target>cite book</target><arg name="author"><space/>Christie, William<space/></arg><arg name="authorlink"><space/></arg><arg name="editor"><space/></arg><arg name="others"><space/></arg><arg name="title"><space/>Lipid analysis: isolation, separation, identification, and structural analysis of lipids<space/></arg><arg name="edition"><space/></arg><arg name="publisher"><space/>Oily Press<space/></arg><arg name="location"><space/>Ayr, Scotland<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="origyear"><space/></arg><arg name="pages"><space/></arg><arg name="quote"><space/></arg><arg name="isbn"><space/>0-9531949-5-7<space/></arg></template></extension><space/>Major dietary sources of cholesterol include<space/><link><target>cheese</target></link>,<space/><link><target>egg yolk</target><trail>s</trail></link>,<space/><link><target>beef</target></link>,<space/><link><target>pork</target></link>,<space/><link><target>poultry</target></link>,<space/><link><target>fish</target></link>, and<space/><link><target>shrimp</target></link>.<extension extension_name='ref' name="USDA"></extension><space/>Human<space/><link><target>breast milk</target></link><space/>also contains significant quantities of cholesterol.<extension extension_name='ref' name="ajcn-breastmilk"><template><target>cite journal</target><arg name="vauthors"><space/>Jensen RG, Hagerty MM, McMahon KE<space/></arg><arg name="title"><space/>Lipids of human milk and infant formulas: a review<space/></arg><arg name="journal"><space/>Am J Clin Nutr<space/></arg><arg name="volume"><space/>31<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>990–1016<space/></arg><arg name="date"><space/>1 June 1978<space/></arg><arg name="pmid"><space/>352132<space/></arg><arg name="url"><space/>http://www.ajcn.org/cgi/reprint/31/6/990<space/></arg><arg name="format"><space/>PDF<space/></arg></template></extension></paragraph><paragraph>From a dietary perspective, cholesterol is not found in significant amounts in plant sources.<extension extension_name='ref' name="USDA"><template><target>cite web</target><arg name="last"><space/></arg><arg name="first"><space/></arg><arg name="title"><space/>USDA National Nutrient Database for Standard Reference, Release 21<space/></arg><arg name="publisher"><space/>United States Department of Agriculture<space/></arg><arg name="url"><space/>http://www.nal.usda.gov/fnic/foodcomp/Data/SR21/nutrlist/sr21w601.pdf<space/></arg><arg name="format">PDF<space/></arg><arg name="accessdate"><space/>2008-10-24</arg></template></extension><extension extension_name='ref' name="Behrman_2005"><template><target>cite journal</target><arg name="vauthors"><space/>Behrman EJ, Gopalan V<space/></arg><arg name="title"><space/>Cholesterol and Plants<space/></arg><arg name="journal"><space/>J. Chem. Educ.<space/></arg><arg name="date">December 2005<space/></arg><arg name="volume"><space/>82<space/></arg><arg name="issue"><space/>12<space/></arg><arg name="pages"><space/>1791<space/></arg><arg name="doi"><space/>10.1021/ed082p1791</arg><arg name="bibcode"><space/>2005JChEd..82.1791B<space/></arg></template></extension><space/>In addition, plant products such as<space/><link><target>avocado</target></link>,<extension extension_name='ref'>http://www.whfoods.com/genpage.php?tname=foodspice&amp;dbid=5</extension><space/><link><target>flax seed</target><trail>s</trail></link><space/>and<space/><link><target>peanut</target><trail>s</trail></link><space/>contain cholesterol-like compounds called<space/><link><target>phytosterols</target></link>, which are believed to compete with cholesterol for absorption in the intestines, thus reducing the absorption of both dietary and bile cholesterol.<extension extension_name='ref' name="ostlund2003"><template><target>cite journal</target><arg name="vauthors"><space/>Ostlund RE, Racette SB, Stenson WF<space/></arg><arg name="title"><space/>Inhibition of cholesterol absorption by phytosterol-replete wheat germ compared with phytosterol-depleted wheat germ<space/></arg><arg name="journal"><space/>Am J Clin Nutr<space/></arg><arg name="volume"><space/>77<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>1385–1589<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>12791614<space/></arg></template></extension><space/><link><target>Phytosterols</target></link><space/>can be supplemented through the use of phytosterol-containing<space/><link><target>functional foods</target></link><space/>or<space/><link><target>nutraceuticals</target></link><space/>that are widely recognized as having a proven<space/><link><target>low-density lipoprotein</target><part>LDL</part></link><space/>cholesterol-lowering efficacy.<extension extension_name='ref'><template><target>cite web</target><arg name="author"><space/>European Food Safety Authority, Journal<space/></arg><arg name="url"><space/>http://www.efsa.europa.eu/en/efsajournal/pub/1813.htm<space/></arg><arg name="title"><space/>Scientific opinion on the substantiation of health claims related to plant sterols and plant stanols and maintenance of normal blood cholesterol concentrations<space/></arg><arg name="year"><space/>2010</arg></template></extension><space/>Current supplemental guidelines recommend doses of phytosterols in the 1.6-3.0&amp;nbsp;grams per day range (Health Canada, EFSA, ATP III,FDA) with a recent meta-analysis demonstrating an 8.8% reduction in LDL-cholesterol at a mean dose of 2.15&amp;nbsp;gram per day.<extension extension_name='ref' name="pmid19091798"><template><target>cite journal</target><arg name="vauthors"><space/>Demonty I, Ras RT, van der Knaap HC, Duchateau GS, Meijer L, Zock PL, Geleijnse JM, Trautwein EA<space/></arg><arg name="title"><space/>Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake<space/></arg><arg name="journal"><space/>J. Nutr.<space/></arg><arg name="volume"><space/>139<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>271–84<space/></arg><arg name="date"><space/>February 2009<space/></arg><arg name="pmid"><space/>19091798<space/></arg><arg name="doi"><space/>10.3945/jn.108.095125<space/></arg></template></extension><space/>However, the benefits of a diet supplemented with phytosterol has been questioned.<extension extension_name='ref' name="pmid21257611"><template><target>cite journal</target><arg name="vauthors"><space/>Weingärtner O, Ulrich C, Lütjohann D, Ismail K, Schirmer SH, Vanmierlo T, Böhm M, Laufs U<space/></arg><arg name="title"><space/>Differential effects on inhibition of cholesterol absorption by plant stanol and plant sterol esters in apoE-/- mice<space/></arg><arg name="journal"><space/>Cardiovasc Res<space/></arg><arg name="volume"><space/>90<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>484–92<space/></arg><arg name="date"><space/>February 2011<space/></arg><arg name="pmid"><space/>21257611<space/></arg><arg name="pmc"><space/>3096304<space/></arg><arg name="doi"><space/>10.1093/cvr/cvr020<space/></arg></template></extension><extension extension_name='ref' name="pmid19158117"><template><target>cite journal</target><arg name="vauthors"><space/>Weingärtner O, Böhm M, Laufs U<space/></arg><arg name="title"><space/>Controversial role of plant sterol esters in the management of hypercholesterolaemia<space/></arg><arg name="journal"><space/>Eur. Heart J.<space/></arg><arg name="volume"><space/>30<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>404–9<space/></arg><arg name="date"><space/>February 2009<space/></arg><arg name="pmid"><space/>19158117<space/></arg><arg name="pmc"><space/>2642922<space/></arg><arg name="doi"><space/>10.1093/eurheartj/ehn580<space/></arg></template></extension></paragraph><paragraph>The fraction of dietary cholesterol which is absorbed varies from 15% to 75%, and is about 50% on average, with the remainder excreted in the feces.<extension extension_name='ref' name="Dietary Phospholipids"><template><target>cite journal</target><arg name="url">http://www.mdpi.com/2072-6643/2/2/116/htm<space/></arg><arg name="title">Dietary Phospholipids and Intestinal Cholesterol Absorption<space/></arg><arg name="author">Cohn, Jeffrey S. et. al.<space/></arg><arg name="journal">Nutrients<space/></arg><arg name="date">February 2010<space/></arg><arg name="volume">2<space/></arg><arg name="issue">2<space/></arg><arg name="pages">116–127<space/></arg><arg name="doi">10.3390/nu2020116</arg></template></extension><space/>Free cholesterol is much more likely to be absorbed than esterified cholesterol, and the proportion of free versus esterified cholesterol varies between different food sources.<extension extension_name='ref'><template><target>cite web</target><arg name="last1">Wilson</arg><arg name="first1">Martha D.</arg><arg name="title">Review of cholesterol absorption with emphasis on dietary and biliary cholesterol</arg><arg name="url">http://citeseerx.ist.psu.edu/viewdoc/summary?doi</arg><arg name="website">http://citeseerx.ist.psu.edu</arg><arg name="accessdate">2015-05-11</arg></template></extension><space/>In February 2015, reversing decades-long recommendations, the USDA Dietary Guidelines Advisory Committee recommended repealing the guideline that Americans limit cholesterol intake, because dietary cholesterol intake was not found to correlate well with serum cholesterol levels. The committee found strong evidence that replacing saturated fat with unsaturated fat would lower<space/><link><target>Low density lipoprotein</target><part>LDL</part></link><space/>cholesterol levels, and that low-fat diets which replace saturated fat with carbohydrates would lower both LDL and<space/><link><target>high density lipoprotein</target><part>HDL</part></link><space/>cholesterol levels.<extension extension_name='ref' name="Dietary Guidelines">http://www.health.gov/dietaryguidelines/2015-scientific-report/PDFs/Scientific-Report-of-the-2015-Dietary-Guidelines-Advisory-Committee.pdf</extension><space/><link><target>Trans fats</target></link><space/>have been shown to reduce levels of HDL while increasing levels of LDL.<extension extension_name='ref' name="pmid9322581"><template><target>cite journal</target><arg name="vauthors"><space/>Ascherio A, Willett WC<space/></arg><arg name="title"><space/>Health effects of trans fatty acids<space/></arg><arg name="journal"><space/>Am. J. Clin. Nutr.<space/></arg><arg name="volume"><space/>66<space/></arg><arg name="issue"><space/>4 Suppl<space/></arg><arg name="pages"><space/>1006S–1010S<space/></arg><arg name="date"><space/>October 1997<space/></arg><arg name="pmid"><space/>9322581<space/></arg><arg name="doi"><space/></arg></template></extension><space/>Based on such evidence and evidence implicating low HDL and high LDL levels in<space/><link><target>cardiovascular disease</target></link><space/>(see<space/><link><target>Hypercholesterolemia</target></link>), many health authorities advocate reducing LDL cholesterol through changes in diet in addition to other lifestyle modifications.<extension extension_name='ref' name="NHS: High cholesterol levels"><template><target>cite web</target><arg name="title"><space/>High cholesterol levels by NHS<space/></arg><arg name="url"><space/>http://www.nhs.uk/conditions/cholesterol/Pages/Introduction.aspx<space/></arg><arg name="publisher"><space/>[[National Health Service]]<space/></arg><arg name="accessdate"><space/>2010-09-14</arg></template></extension></paragraph><heading level='3'>Biosynthesis</heading><paragraph>All animal cells manufacture cholesterol for their use, with relative production rates varying by cell type and organ function. About 2025% of total daily cholesterol production occurs in the<space/><link><target>liver</target></link>; other sites of higher synthesis rates include the<space/><link><target>intestines</target></link>,<space/><link><target>adrenal gland</target><trail>s</trail></link>, and<space/><link><target>reproductive organ</target><trail>s</trail></link>. Synthesis within the body starts with the<space/><link><target>mevalonate pathway</target></link><space/>where two molecules of<space/><link><target>acetyl CoA</target></link><space/>condense to form<space/><link><target>acetoacetyl-CoA</target></link>. This is followed by a second condensation between<space/><link><target>acetyl CoA</target></link><space/>and<space/><link><target>acetoacetyl-CoA</target></link><space/>to form<space/><link><target>3-hydroxy-3-methylglutaryl CoA</target></link><space/>(<link><target>HMG-CoA</target></link>).<extension extension_name='ref' name="Mehta"><template><target>cite web</target><arg name="url">http://pharmaxchange.info/press/2013/09/biosynthesis-and-regulation-of-cholesterol-animation/</arg><arg name="title">Biosynthesis and Regulation of Cholesterol (with Animation)</arg><arg name="work">PharmaXChange.info</arg></template></extension><space/>This molecule is then reduced to<space/><link><target>mevalonate</target></link><space/>by the enzyme<space/><link><target>HMG-CoA reductase</target></link>. Production of<space/><link><target>mevalonate</target></link><space/>is the rate-limiting and irreversible step in cholesterol synthesis and is the site of action for<space/><link><target>statins</target></link><space/>(a class of cholesterol lowering drugs).</paragraph><paragraph>Mevalonate is finally converted to<space/><link><target>isopentenyl pyrophosphate</target></link><space/>(IPP) through two phosphorylation steps and one decarboxylation step that requires<space/><link><target>Adenosine triphosphate</target><part>ATP</part></link>. Three molecules of isopentenyl pyrophosphate condense to form<space/><link><target>farnesyl pyrophosphate</target></link><space/>through the action of geranyl transferase. Two molecules of farnesyl pyrophosphate then condense to form<space/><link><target>squalene</target></link><space/>by the action of<space/><link><target>squalene synthase</target></link><space/>in the<space/><link><target>endoplasmic reticulum</target></link>.<extension extension_name='ref' name="Mehta"></extension><space/>Oxidosqualene cyclase then cyclizes squalene to form<space/><link><target>lanosterol</target></link>. Finally, lanosterol is converted to cholesterol through a 19-step process.<extension extension_name='ref'><template><target>cite book</target><arg name="author"><space/>Berg J<space/></arg><arg name="title"><space/>Biochemistry<space/></arg><arg name="year"><space/>2002<space/></arg><arg name="publisher"><space/>WH Freeman<space/></arg><arg name="location"><space/>New York<space/></arg><arg name="isbn"><space/>0-7167-3051-0<space/></arg></template></extension><extension extension_name='ref' name="isbn0-7167-2009-4"><template><target>cite book</target><arg name="author"><space/>Rhodes CM Stryer L, Tasker R<space/></arg><arg name="title"><space/>Biochemistry<space/></arg><arg name="edition"><space/>4th<space/></arg><arg name="publisher"><space/>W.H. Freeman<space/></arg><arg name="location"><space/>San Francisco<space/></arg><arg name="year"><space/>1995<space/></arg><arg name="pages"><space/>280, 703<space/></arg><arg name="isbn"><space/>0-7167-2009-4<space/></arg></template></extension></paragraph><paragraph><link><target>Konrad Bloch</target></link><space/>and<space/><link><target>Feodor Lynen</target></link><space/>shared the<space/><link><target>Nobel Prize in Physiology or Medicine</target></link><space/>in 1964 for their discoveries concerning the mechanism and regulation of cholesterol and<space/><link><target>fatty acid metabolism</target></link>.</paragraph><heading level='3'>Regulation of cholesterol synthesis</heading><paragraph>Biosynthesis of cholesterol is directly regulated by the cholesterol levels present, though the<space/><link><target>homeostasis</target><part>homeostatic</part></link><space/>mechanisms involved are only partly understood. A higher intake from food leads to a net decrease in endogenous production, whereas lower intake from food has the opposite effect. The main regulatory mechanism is the sensing of<space/><link><target>intracellular</target></link><space/>cholesterol in the<space/><link><target>endoplasmic reticulum</target></link><space/>by the<space/><link><target>protein</target></link><space/><link><target>sterol regulatory element binding protein</target><part>SREBP</part></link><space/>(sterol regulatory element-binding protein 1 and 2).<extension extension_name='ref' name="pmid17666007"><template><target>cite journal</target><arg name="vauthors"><space/>Espenshade PJ, Hughes AL<space/></arg><arg name="title"><space/>Regulation of sterol synthesis in eukaryotes<space/></arg><arg name="journal"><space/>Annu. Rev. Genet.<space/></arg><arg name="volume"><space/>41<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>401–27<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="pmid"><space/>17666007<space/></arg><arg name="doi"><space/>10.1146/annurev.genet.41.110306.130315<space/></arg></template></extension><space/>In the presence of cholesterol, SREBP is bound to two other proteins:<space/><link><target>SREBP cleavage-activating protein</target><part>SCAP</part></link><space/>(SREBP cleavage-activating protein) and<space/><link><target>INSIG-1</target></link>. When cholesterol levels fall, INSIG-1 dissociates from the SREBP-SCAP complex, which allows the complex to migrate to the<space/><link><target>Golgi apparatus</target></link>. Here SREBP is cleaved by S1P and S2P (site-1 protease and site-2 protease), two enzymes that are activated by SCAP when cholesterol levels are low.</paragraph><paragraph>The cleaved SREBP then migrates to the nucleus, and acts as a<space/><link><target>transcription factor</target></link><space/>to bind to the sterol regulatory element (SRE), which stimulates the<space/><link><target>Transcription (genetics)</target><part>transcription</part></link><space/>of many genes. Among these are the low-density lipoprotein (<link><target>Low-density lipoprotein</target><part>LDL</part></link>) receptor and<space/><link><target>HMG-CoA reductase</target></link>. The LDL receptor scavenges circulating LDL from the bloodstream, whereas HMG-CoA reductase leads to an increase of endogenous production of cholesterol.<extension extension_name='ref'><template><target>cite journal</target><arg name="vauthors"><space/>Brown MS, Goldstein JL<space/></arg><arg name="title"><space/>The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor<space/></arg><arg name="journal"><space/>Cell<space/></arg><arg name="volume"><space/>89<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>331–40<space/></arg><arg name="year"><space/>1997<space/></arg><arg name="pmid"><space/>9150132<space/></arg><arg name="doi"><space/>10.1016/S0092-8674(00)80213-5<space/></arg></template></extension><space/>A large part of this signaling pathway was clarified by Dr.<space/><link><target>Michael S. Brown</target></link><space/>and Dr.<space/><link><target>Joseph L. Goldstein</target></link><space/>in the 1970s. In 1985, they received the<space/><link><target>Nobel Prize in Physiology or Medicine</target></link><space/>for their work. Their subsequent work shows how the SREBP pathway regulates expression of many genes that control lipid formation and metabolism and body fuel allocation.</paragraph><paragraph>Cholesterol synthesis can also be turned off when cholesterol levels are high. HMG-CoA reductase contains both a cytosolic domain (responsible for its catalytic function) and a membrane domain. The membrane domain senses signals for its degradation. Increasing concentrations of cholesterol (and other sterols) cause a change in this domain's oligomerization state, which makes it more susceptible to destruction by the<space/><link><target>proteosome</target></link>. This enzyme's activity can also be reduced by phosphorylation by an AMP-activated protein<space/><link><target>kinase</target></link>. Because this kinase is activated by AMP, which is produced when ATP is hydrolyzed, it follows that cholesterol synthesis is halted when ATP levels are low.<extension extension_name='ref' name="isbn0-7167-4955-6"><template><target>cite book</target><arg name="author"><space/>Tymoczko, John L.; Stryer Berg Tymoczko; Stryer, Lubert; Berg, Jeremy Mark<space/></arg><arg name="authorlink"><space/></arg><arg name="editor"><space/></arg><arg name="others"><space/></arg><arg name="title"><space/>Biochemistry<space/></arg><arg name="edition"><space/></arg><arg name="publisher"><space/>W.H. Freeman<space/></arg><arg name="location"><space/>San Francisco<space/></arg><arg name="year"><space/>2002<space/></arg><arg name="origyear"><space/></arg><arg name="pages"><space/>726–727<space/></arg><arg name="quote"><space/></arg><arg name="isbn"><space/>0-7167-4955-6<space/></arg><arg name="oclc"><space/></arg><arg name="doi"><space/></arg><arg name="url"><space/></arg><arg name="accessdate"><space/></arg></template></extension></paragraph><heading level='3'>Plasma transport and regulation of absorption</heading><paragraph><template><target>See also</target><arg>Blood lipids</arg></template></paragraph><paragraph>Cholesterol is only slightly soluble in<space/><link><target>water</target></link>; it dissolves into the (water-based) bloodstream only at exceedingly small concentrations. Instead, cholesterol is transported inside<space/><link><target>lipoprotein</target><trail>s</trail></link>, complex discoidal particles with exterior<space/><link><target>amphiphile</target><part>amphiphilic</part></link><space/>proteins and lipids, whose outward-facing surfaces are water-soluble and inward-facing surfaces are lipid-soluble.<space/><link><target>Triglyceride</target><trail>s</trail></link><space/>and cholesterol esters are carried internally. Phospholipids and cholesterol, being amphipathic, are transported in the monolayer surface of the lipoprotein particle.</paragraph><paragraph>There are several types of lipoproteins in the blood. In order of increasing density, they are<space/><link><target>chylomicron</target><trail>s</trail></link>,<space/><link><target>very-low-density lipoprotein</target></link><space/>(VLDL),<space/><link><target>low-density lipoprotein</target></link><space/>(LDL),<space/><link><target>intermediate-density lipoprotein</target></link><space/>(IDL), and<space/><link><target>high-density lipoprotein</target></link><space/>(HDL). Lower protein/lipid ratios make for less dense lipoproteins. Cholesterol within different lipoproteins is identical, although some is carried as &quot;free&quot; alcohol, while others as fatty acyl esters, known also as cholesterol esters.</paragraph><paragraph>Lipoproteins contain<space/><link><target>apolipoproteins</target></link>, which bind to specific receptors on cell membranes, directing their lipid payload to specific tissues. Lipoprotein particles thus include these molecular addresses, which determine the start- and end points of cholesterol transport.</paragraph><paragraph>Chylomicrons, the least dense cholesterol transport molecules, contain<space/><link><target>apolipoprotein B-48</target></link>,<space/><link><target>apolipoprotein C</target></link>, and<space/><link><target>apolipoprotein E</target></link><space/>in their shells. Chylomicrons carry fats from the intestine to muscle and other tissues in need of fatty acids for energy or fat production. Unused cholesterol remains in more cholesterol-rich chylomicron remnants, and taken up from here to the bloodstream by the liver.</paragraph><paragraph>VLDL molecules are produced by the liver from triacylglycerol and cholesterol which was not used in the synthesis of bile acids. These molecules contain<space/><link><target>apolipoprotein B100</target></link><space/>and<space/><link><target>apolipoprotein E</target></link><space/>in their shells, and are degraded by<space/><link><target>lipoprotein lipase</target></link><space/>on the blood vessel wall to IDL.</paragraph><paragraph>Blood vessels cleave and absorb triacylglycerol from IDL molecules, increasing the concentration of cholesterol. IDL molecules are then consumed in two processes: half is metabolized by<space/><link><target>HTGL</target></link><space/>and taken up by the LDL receptor on the liver cell surfaces, while the other half continues to lose triacylglycerols in the bloodstream until they become LDL molecules, with the highest concentration of cholesterol within them.</paragraph><paragraph>LDL particles are the major blood cholesterol carriers. Each one contains approximately 1,500 molecules of cholesterol ester. LDL molecule shells contain just one molecule of<space/><link><target>apolipoprotein B100</target></link>, recognized by<space/><link><target>LDL receptor</target><trail>s</trail></link><space/>in peripheral tissues. Upon binding of<space/><link><target>apolipoprotein B100</target></link>, many LDL receptors concentrate in<space/><link><target>clathrin</target></link>-coated pits. Both LDL and its receptor form vesicles within a cell via<space/><link><target>endocytosis</target></link>. These vesicles then fuse with a<space/><link><target>lysosome</target></link>, where the<space/><link><target>Lysosomal lipase</target><part>lysosomal acid lipase</part></link><space/>enzyme hydrolyzes the cholesterol esters. The cholesterol can then be used for membrane biosynthesis or esterified and stored within the cell, so as to not interfere with the cell membranes.</paragraph><paragraph>LDL receptors are used up during cholesterol absorption, and its synthesis is regulated by<space/><link><target>SREBP</target></link>, the same protein that controls the synthesis of cholesterol<space/><italics>de novo</italics>, according to its presence inside the cell. A cell with abundant cholesterol will have its LDL receptor synthesis blocked, to prevent new cholesterol in LDL molecules from being taken up. Conversely, LDL receptor synthesis proceeds when a cell is deficient in cholesterol.</paragraph><paragraph>When this process becomes unregulated, LDL molecules without receptors begin to appear in the blood. These LDL molecules are oxidized and taken up by<space/><link><target>macrophages</target></link>, which become engorged and form foam cells. These foam cells often become trapped in the walls of blood vessels and contribute to<space/><link><target>atheroma</target><part>atherosclerotic plaque</part></link><space/>formation. Differences in cholesterol homeostasis affect the development of early atherosclerosis (carotid intima-media thickness).<extension extension_name='ref' name="pmid20976107"><template><target>cite journal</target><arg name="vauthors"><space/>Weingärtner O, Pinsdorf T, Rogacev KS, Blömer L, Grenner Y, Gräber S, Ulrich C, Girndt M, Böhm M, Fliser D, Laufs U, Lütjohann D, Heine GH<space/></arg><arg name="title"><space/>The relationships of markers of cholesterol homeostasis with carotid intima-media thickness<space/></arg><arg name="journal"><space/>PLoS ONE<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>e13467<space/></arg><arg name="year"><space/>2010<space/></arg><arg name="pmid"><space/>20976107<space/></arg><arg name="pmc"><space/>2956704<space/></arg><arg name="doi"><space/>10.1371/journal.pone.0013467<space/></arg><arg name="editor1-last"><space/>Federici<space/></arg><arg name="editor1-first"><space/>Massimo<space/></arg><arg name="bibcode"><space/>2010PLoSO...513467W<space/></arg></template></extension><space/>These plaques are the main causes of heart attacks, strokes, and other serious medical problems, leading to the association of so-called LDL cholesterol (actually a<space/><link><target>lipoprotein</target></link>) with &quot;bad&quot; cholesterol.<extension extension_name='ref' name="isbn0-7167-4955-6"></extension></paragraph><paragraph>HDL particles are thought to transport cholesterol back to the liver, either for excretion or for other tissues that synthesize hormones, in a process known as<space/><link><target>reverse cholesterol transport</target></link><space/>(RCT).<extension extension_name='ref' name="pmid15976321"><template><target>cite journal</target><arg name="vauthors"><space/>Lewis GF, Rader DJ<space/></arg><arg name="title"><space/>New insights into the regulation of HDL metabolism and reverse cholesterol transport<space/></arg><arg name="journal"><space/>Circ. Res.<space/></arg><arg name="volume"><space/>96<space/></arg><arg name="issue"><space/>12<space/></arg><arg name="pages"><space/>1221–32<space/></arg><arg name="date"><space/>June 2005<space/></arg><arg name="pmid"><space/>15976321<space/></arg><arg name="doi"><space/>10.1161/01.RES.0000170946.56981.5c<space/></arg></template></extension><space/>Large numbers of HDL particles correlates with better health outcomes.,<extension extension_name='ref' name="pmid2642759"><template><target>cite journal</target><arg name="vauthors"><space/>Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Bangdiwala S, Tyroler HA<space/></arg><arg name="title"><space/>High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies<space/></arg><arg name="journal"><space/>Circulation<space/></arg><arg name="volume"><space/>79<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>8–15<space/></arg><arg name="date"><space/>January 1989<space/></arg><arg name="pmid"><space/>2642759<space/></arg><arg name="doi"><space/>10.1161/01.CIR.79.1.8<space/></arg></template></extension><space/>whereas low numbers of HDL particles is associated with<space/><link><target>atheroma</target><trail>tous</trail></link><space/>disease progression in the arteries.</paragraph><heading level='3'>Metabolism, recycling and excretion</heading><paragraph>Cholesterol is susceptible to oxidation and easily forms oxygenated derivatives known as<space/><link><target>oxysterol</target><trail>s</trail></link>. Three different mechanisms can form these; autoxidation, secondary oxidation to lipid peroxidation, and cholesterol-metabolizing enzyme oxidation. A great interest in oxysterols arose when they were shown to exert inhibitory actions on cholesterol biosynthesis.<extension extension_name='ref' name="pmid663671"><template><target>cite journal</target><arg name="vauthors"><space/>Kandutsch AA, Chen HW, Heiniger HJ<space/></arg><arg name="title"><space/>Biological activity of some oxygenated sterols<space/></arg><arg name="journal"><space/>Science<space/></arg><arg name="volume"><space/>201<space/></arg><arg name="issue"><space/>4355<space/></arg><arg name="pages"><space/>498–501<space/></arg><arg name="date"><space/>August 1978<space/></arg><arg name="pmid"><space/>663671<space/></arg><arg name="doi"><space/>10.1126/science.663671<space/></arg><arg name="bibcode"><space/>1978Sci...201..498K<space/></arg></template></extension><space/>This finding became known as the oxysterol hypothesis. Additional roles for oxysterols in human physiology include their: participation in bile acid biosynthesis, function as transport forms of cholesterol, and regulation of gene transcription.<extension extension_name='ref' name="pmid11111082"><template><target>cite journal</target><arg name="vauthors"><space/>Russell DW<space/></arg><arg name="title"><space/>Oxysterol biosynthetic enzymes<space/></arg><arg name="journal"><space/>Biochim. Biophys. Acta<space/></arg><arg name="volume"><space/>1529<space/></arg><arg name="issue"><space/>1–3<space/></arg><arg name="pages"><space/>126–35<space/></arg><arg name="date"><space/>December 2000<space/></arg><arg name="pmid"><space/>11111082<space/></arg><arg name="doi"><space/>10.1016/S1388-1981(00)00142-6<space/></arg></template></extension></paragraph><paragraph>In biochemical experiments radiolabelled forms of cholesterol, such as tritiated-cholesterol are used. These derivatives undergo degradation upon storage and it is essential to purify cholesterol prior to use. Cholesterol can be purified using small Sephadex LH-20 columns.<extension extension_name='ref' name="HanukogluJefcoate1980"><template><target>cite journal</target><arg name="vauthors"><space/>Hanukoglu I, Jefcoate CR<space/></arg><arg name="title"><space/>Pregnenolone separation from cholesterol using Sephadex LH-20 mini-columns</arg><arg name="journal">Journal of Chromatography A<space/></arg><arg name="volume"><space/>190<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="year"><space/>1980<space/></arg><arg name="pages"><space/>256–262<space/></arg><arg name="doi"><space/>10.1016/S0021-9673(00)85545-4<space/></arg></template></extension></paragraph><paragraph>Cholesterol is oxidized by the liver into a variety of<space/><link><target>bile acids</target></link>.<extension extension_name='ref' name="pmid8001744"><template><target>cite journal</target><arg name="vauthors"><space/>Javitt NB<space/></arg><arg name="title"><space/>Bile acid synthesis from cholesterol: regulatory and auxiliary pathways<space/></arg><arg name="journal"><space/>FASEB J.<space/></arg><arg name="volume"><space/>8<space/></arg><arg name="issue"><space/>15<space/></arg><arg name="pages"><space/>1308–11<space/></arg><arg name="date"><space/>December 1994<space/></arg><arg name="pmid"><space/>8001744<space/></arg><arg name="doi"><space/></arg></template></extension><space/>These, in turn, are<space/><link><target>phase 2 reaction</target><part>conjugated</part></link><space/>with<space/><link><target>glycine</target></link>,<space/><link><target>taurine</target></link>,<space/><link><target>glucuronic acid</target></link>, or<space/><link><target>sulfate</target></link>. A mixture of conjugated and nonconjugated bile acids, along with cholesterol itself, is excreted from the<space/><link><target>liver</target></link><space/>into the<space/><link><target>bile</target></link>. Approximately 95% of the bile acids are reabsorbed from the intestines, and the remainder are lost in the feces.<extension extension_name='ref' name="pmid12529265"><template><target>cite journal</target><arg name="vauthors"><space/>Wolkoff AW, Cohen DE<space/></arg><arg name="title"><space/>Bile acid regulation of hepatic physiology: I. Hepatocyte transport of bile acids<space/></arg><arg name="journal"><space/>Am. J. Physiol. Gastrointest. Liver Physiol.<space/></arg><arg name="volume"><space/>284<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>G175–9<space/></arg><arg name="date"><space/>February 2003<space/></arg><arg name="pmid"><space/>12529265<space/></arg><arg name="doi"><space/>10.1152/ajpgi.00409.2002<space/></arg><arg name="doi_brokendate"><space/>2015-01-01<space/></arg></template></extension><space/>The excretion and reabsorption of bile acids forms the basis of the<space/><link><target>enterohepatic circulation</target></link>, which is essential for the digestion and absorption of dietary fats. Under certain circumstances, when more concentrated, as in the<space/><link><target>gallbladder</target></link>, cholesterol crystallises and is the major constituent of most<space/><link><target>gallstone</target><trail>s</trail></link>. Although,<space/><link><target>lecithin</target></link><space/>and<space/><link><target>bilirubin</target></link><space/>gallstones also occur, but less frequently.<extension extension_name='ref' name="pmid17547709"><template><target>cite journal</target><arg name="vauthors"><space/>Marschall HU, Einarsson C<space/></arg><arg name="title"><space/>Gallstone disease<space/></arg><arg name="journal"><space/>J. Intern. Med.<space/></arg><arg name="volume"><space/>261<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>529–42<space/></arg><arg name="date"><space/>June 2007<space/></arg><arg name="pmid"><space/>17547709<space/></arg><arg name="doi"><space/>10.1111/j.1365-2796.2007.01783.x<space/></arg></template></extension>Every day, up to 1 g of cholesterol enters the colon. This cholesterol originates from the diet, bile, and desquamated intestinal cells, and can be metabolized by the colonic bacteria. Cholesterol is converted mainly into<space/><link><target>coprostanol</target></link>, a nonabsorbable sterol that is excreted in the feces. A cholesterol-reducing bacterium origin has been isolated from human feces.<extension extension_name='ref' name="pmid17616613"><template><target>cite journal</target><arg name="vauthors"><space/>Gérard P, Lepercq P, Leclerc M, Gavini F, Raibaud P, Juste C<space/></arg><arg name="title"><space/>Bacteroides sp. strain D8, the first cholesterol-reducing bacterium isolated from human feces<space/></arg><arg name="journal"><space/>Appl. Environ. Microbiol.<space/></arg><arg name="volume"><space/>73<space/></arg><arg name="issue"><space/>18<space/></arg><arg name="pages"><space/>5742–9<space/></arg><arg name="date"><space/>September 2007<space/></arg><arg name="pmid"><space/>17616613<space/></arg><arg name="pmc"><space/>2074900<space/></arg><arg name="doi"><space/>10.1128/AEM.02806-06<space/></arg></template></extension><template><target>Primary source-inline</target><arg name="date">December 2011</arg></template></paragraph><paragraph>Although cholesterol is a steroid generally associated with mammals, the human pathogen<space/><italics><link><target>Mycobacterium tuberculosis</target></link></italics><space/>is able to completely degrade this molecule and contains a large number of genes that are regulated by its presence.<extension extension_name='ref'><template><target>cite journal</target><arg name="vauthors"><space/>Wipperman MF, Sampson NS, Thomas ST<space/></arg><arg name="title"><space/>Pathogen roid rage: Cholesterol utilization by Mycobacterium tuberculosis<space/></arg><arg name="journal"><space/>Crit. Rev. Biochem. Mol. Biol.<space/></arg><arg name="volume"><space/>49<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>269–93<space/></arg><arg name="date"><space/>2014<space/></arg><arg name="pmid"><space/>24611808<space/></arg><arg name="doi"><space/>10.3109/10409238.2014.895700<space/></arg><arg name="url"><space/>http://informahealthcare.com/doi/abs/10.3109/10409238.2014.895700<space/></arg></template></extension><space/>Many of these cholesterol-regulated genes are<space/><link><target>Homology (biology)</target><part>homologues</part></link><space/>of<space/><link><target>fatty acid</target></link><space/><link><target>-oxidation</target></link><space/>genes, but have evolved in such a way as to bind large steroid substrates like cholesterol.<extension extension_name='ref'><template><target>cite journal</target><arg name="vauthors"><space/>Thomas ST, Sampson NS<space/></arg><arg name="title"><space/>Mycobacterium tuberculosis utilizes a unique heterotetrameric structure for dehydrogenation of the cholesterol side chain<space/></arg><arg name="journal"><space/>Biochemistry<space/></arg><arg name="volume"><space/>52<space/></arg><arg name="issue"><space/>17<space/></arg><arg name="pages"><space/>2895–2904<space/></arg><arg name="date"><space/>2013<space/></arg><arg name="pmid"><space/>23560677<space/></arg><arg name="pmc"><space/>3726044<space/></arg><arg name="doi"><space/>10.1021/bi4002979<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="vauthors"><space/>Wipperman MF, Yang M, Thomas ST, Sampson NS<space/></arg><arg name="title"><space/>Shrinking the FadE Proteome of ''Mycobacterium tuberculosis'': Insights into Cholesterol Metabolism through Identification of an α<sub>2</sub>β<sub>2</sub><space/>Heterotetrameric Acyl Coenzyme A Dehydrogenase Family<space/></arg><arg name="journal"><space/>J. Bacteriol.<space/></arg><arg name="volume"><space/>195<space/></arg><arg name="issue"><space/>19<space/></arg><arg name="pages"><space/>4331–4341<space/></arg><arg name="date"><space/>2013<space/></arg><arg name="pmid"><space/>23836861<space/></arg><arg name="doi"><space/>10.1128/JB.00502-13<space/></arg></template></extension></paragraph><heading level='2'>Clinical significance</heading><heading level='3'>Hypercholesterolemia</heading><paragraph><template><target>Main</target><arg>hypercholesterolemia</arg><arg>lipid hypothesis</arg></template>According to the<space/><link><target>lipid hypothesis</target></link>, since cholesterol (like all fat molecules) is transported around the body (in the<space/><link><target>Extracellular fluid</target><part>water outside cells</part></link>) inside<space/><link><target>lipoprotein</target></link><space/>particles, elevated cholesterol concentrations (<link><target>hypercholesterolemia</target></link>)&amp;nbsp; potentially offers a lower cost way to detect elevated concentrations of<space/><link><target>Low-density lipoprotein</target><part>LDL</part></link><space/>particles; possibly even low concentrations of functional<space/><link><target>High-density lipoprotein</target><part>HDL</part></link><space/>particles&amp;nbsp; both variations strongly associated with<space/><link><target>cardiovascular disease</target></link><space/>because LDL particles promote<space/><link><target>atheroma</target></link><space/>development in arteries (<link><target>atherosclerosis</target></link>).</paragraph><paragraph>This atherosclerotic disease process, over decades, leads to<space/><link><target>myocardial infarction</target></link><space/>(heart attack),<space/><link><target>stroke</target></link>, and<space/><link><target>peripheral vascular disease</target></link>. Since higher blood LDL, especially higher LDL particle concentrations and smaller LDL particle size, contribute to this process more than the cholesterol content of the HDL particles,<extension extension_name='ref' name="pmid18375431"><template><target>cite journal</target><arg name="vauthors"><space/>Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL<space/></arg><arg name="title"><space/>Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation<space/></arg><arg name="journal"><space/>Diabetes Care<space/></arg><arg name="volume"><space/>31<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>811–22<space/></arg><arg name="date"><space/>April 2008<space/></arg><arg name="pmid"><space/>18375431<space/></arg><arg name="doi"><space/>10.2337/dc08-9018<space/></arg></template></extension><space/>LDL particles are often termed &quot;bad cholesterol&quot; because they have been linked to atheroma formation. On the other hand, high concentrations of functional HDL, which can remove cholesterol from cells and atheroma, offer protection and are sometimes referred to as &quot;good cholesterol&quot;. These balances are mostly genetically determined, but can be changed by body build,<space/><link><target>medication</target><trail>s</trail></link>, food choices, and other factors.<extension extension_name='ref' name="pmid12957096"><template><target>cite journal</target><arg name="vauthors"><space/>Durrington P<space/></arg><arg name="title"><space/>Dyslipidaemia<space/></arg><arg name="journal"><space/>Lancet<space/></arg><arg name="volume"><space/>362<space/></arg><arg name="issue"><space/>9385<space/></arg><arg name="pages"><space/>717–31<space/></arg><arg name="date"><space/>August 2003<space/></arg><arg name="pmid"><space/>12957096<space/></arg><arg name="doi"><space/>10.1016/S0140-6736(03)14234-1<space/></arg></template></extension><space/><link><target>Resistin</target></link>, a protein secreted by fat tissue, has been shown to increase the production of LDL in human liver cells and also degrades LDL receptors in the<space/><link><target>liver</target></link>. As a result, the liver is less able to clear cholesterol from the bloodstream.<space/><link><target>Resistin</target></link><space/>accelerates the accumulation of LDL in arteries, increasing the risk of heart disease. Resistin also adversely impacts the effects of statins, the main cholesterol-reducing drug used in the treatment and prevention of cardiovascular disease. See:.<extension extension_name='ref' name="Canadian scientists discover cause of high cholesterol"><template><target>cite web</target><arg name="url">http://www.heartandstroke.com/site/apps/nlnet/content2.aspx?c</arg><arg name="title">Canadian scientists discover cause of high cholesterol</arg></template></extension></paragraph><paragraph>Conditions with elevated concentrations of oxidized LDL particles, especially &quot;small dense LDL&quot; (sdLDL) particles, are associated with<space/><link><target>atheroma</target></link><space/>formation in the walls of<space/><link><target>artery</target><part>arteries</part></link>, a condition known as<space/><link><target>atherosclerosis</target></link>, which is the principal cause of<space/><link><target>coronary heart disease</target></link><space/>and other forms of<space/><link><target>cardiovascular disease</target></link>. In contrast, HDL particles (especially large HDL) have been identified as a mechanism by which cholesterol and inflammatory mediators can be removed from atheroma. Increased concentrations of HDL correlate with lower rates of atheroma progressions and even regression. A 2007 study pooling data on almost 900,000 subjects in 61 cohorts demonstrated that blood total cholesterol levels have an exponential effect on cardiovascular and total mortality, with the association more pronounced in younger subjects. Still, because cardiovascular disease is relatively rare in the younger population, the impact of high cholesterol on health is still larger in older people.<extension extension_name='ref' name="pmid18061058"><template><target>cite journal</target><arg name="vauthors"><space/>Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R<space/></arg><arg name="title"><space/>Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths<space/></arg><arg name="journal"><space/>Lancet<space/></arg><arg name="volume"><space/>370<space/></arg><arg name="issue"><space/>9602<space/></arg><arg name="pages"><space/>1829–39<space/></arg><arg name="date"><space/>December 2007<space/></arg><arg name="pmid"><space/>18061058<space/></arg><arg name="doi"><space/>10.1016/S0140-6736(07)61778-4<space/></arg></template></extension></paragraph><paragraph>Elevated levels of the lipoprotein fractions, LDL, IDL and VLDL are regarded as atherogenic (prone to cause atherosclerosis).<extension extension_name='ref' name="NCEPIII"><template><target>cite web</target><arg name="title"><space/>Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report<space/></arg><arg name="publisher"><space/>National Institutes of Health. National Heart, Lung and Blood Institute<space/></arg><arg name="url"><space/>http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf<space/></arg><arg name="format">PDF<space/></arg><arg name="accessdate"><space/>2008-10-27</arg></template></extension><space/>Levels of these fractions, rather than the total cholesterol level, correlate with the extent and progress of atherosclerosis. Conversely, the total cholesterol can be within normal limits, yet be made up primarily of small LDL and small HDL particles, under which conditions atheroma growth rates would still be high. Recently, a<space/><italics>post hoc</italics><space/>analysis of the IDEAL and the EPIC prospective studies found an association between high levels of HDL cholesterol (adjusted for apolipoprotein A-I and apolipoprotein B) and increased risk of cardiovascular disease, casting doubt on the cardioprotective role of &quot;good cholesterol&quot;.<extension extension_name='ref' name="pmid18261682"><template><target>cite journal</target><arg name="vauthors"><space/>van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT, Kastelein JJ<space/></arg><arg name="title"><space/>High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies<space/></arg><arg name="journal"><space/>J. Am. Coll. Cardiol.<space/></arg><arg name="volume"><space/>51<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>634–42<space/></arg><arg name="date"><space/>February 2008<space/></arg><arg name="pmid"><space/>18261682<space/></arg><arg name="doi"><space/>10.1016/j.jacc.2007.09.060<space/></arg></template></extension></paragraph><paragraph>Elevated cholesterol levels are treated with a strict diet consisting of low saturated fat, trans fat-free, low cholesterol foods,<extension extension_name='ref' name="urlHow Can I Lower High Cholesterol?"><template><target>cite web</target><arg name="url"><space/>http://www.heart.org/idc/groups/heart-public/@wcm/@hcm/documents/downloadable/ucm_300460.pdf<space/></arg><arg name="title"><space/>How Can I Lower High Cholesterol<space/></arg><arg name="author"><space/></arg><arg name="authorlink"><space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="publisher"><space/>American Heart Association<space/></arg><arg name="pages"><space/></arg><arg name="archiveurl"><space/></arg><arg name="archivedate"><space/></arg><arg name="quote"><space/></arg><arg name="accessdate"><space/>2011-04-03</arg></template></extension><extension extension_name='ref' name="urlGood Cholesterol Foods"><template><target>cite web</target><arg name="url"><space/>http://good-cholesterol-foods.net<space/></arg><arg name="title"><space/>Good Cholesterol Foods<space/></arg><arg name="author"><space/></arg><arg name="authorlink"><space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="publisher"><space/>Good Cholesterol Foods<space/></arg><arg name="pages"><space/></arg><arg name="archiveurl"><space/></arg><arg name="archivedate"><space/></arg><arg name="quote"><space/></arg><arg name="accessdate"><space/>2011-04-03</arg></template></extension><space/>often followed by one of various<space/><link><target>hypolipidemic agent</target><trail>s</trail></link>, such as<space/><link><target>statin</target><trail>s</trail></link>,<space/><link><target>fibrate</target><trail>s</trail></link>, cholesterol absorption inhibitors, nicotinic acid derivatives or bile acid sequestrants.<extension extension_name='ref' name="NICE67"><template><target>NICE</target><arg>67</arg><arg>Lipid modification</arg><arg>2008</arg></template></extension><space/>Extreme cases have previously been treated with<space/><link><target>partial ileal bypass surgery</target></link>, which has now been superseded by medication.<space/><link><target>Apheresis</target></link>-based treatments are still used for very severe hyperlipidemias that are either unresponsive to treatment or require rapid lowering of blood lipids.<extension extension_name='ref'>Matthew Lui, Ross Garberich, Craig Strauss, Thomas Davin, and Thomas Knickelbine,<space/><link type='external' href='http://www.hindawi.com/journals/jl/2014/864317/'>Usefulness of Lipid Apheresis in the Treatment of Familial Hypercholesterolemia</link><space/>Journal of Lipids, vol. 2014, Article ID 864317, 6 pages, 2014. doi:10.1155/2014/864317</extension></paragraph><paragraph>Multiple human trials using HMG-CoA reductase inhibitors, known as<space/><link><target>statins</target></link>, have repeatedly confirmed that changing lipoprotein transport patterns from unhealthy to healthier patterns significantly lowers cardiovascular disease event rates, even for people with cholesterol values currently considered low for adults.<extension extension_name='ref'><template><target>cite journal</target><arg name="vauthors"><space/>Kizer JR, Madias C, Wilner B, Vaughan CJ, Mushlin AI, Trushin P, Gotto AM, Pasternak RC<space/></arg><arg name="title"><space/>Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy.<space/></arg><arg name="journal"><space/>The American journal of cardiology<space/></arg><arg name="volume"><space/>105<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>1289–96<space/></arg><arg name="date"><space/>May 1, 2010<space/></arg><arg name="pmid"><space/>20403481<space/></arg><arg name="pmc"><space/>2917836<space/></arg><arg name="doi"><space/>10.1016/j.amjcard.2009.12.051<space/></arg></template></extension><space/>Studies have also found that statins reduce atheroma progression.<extension extension_name='ref' name="pmid18666843"><template><target>cite journal</target><arg name="vauthors"><space/>Nicholls SJ<space/></arg><arg name="title"><space/>Rosuvastatin and progression of atherosclerosis<space/></arg><arg name="journal"><space/>Expert Rev Cardiovasc Ther<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="issue"><space/>7<space/></arg><arg name="pages"><space/>925–33<space/></arg><arg name="date"><space/>August 2008<space/></arg><arg name="pmid"><space/>18666843<space/></arg><arg name="doi"><space/>10.1586/14779072.6.7.925<space/></arg></template></extension><space/>As a result, people with a history of cardiovascular disease may derive benefit from statins irrespective of their cholesterol levels (total cholesterol below 5.0&amp;nbsp;mmol/L [193&amp;nbsp;mg/dL]),<extension extension_name='ref' name="pmid12114036"><template><target>cite journal</target><arg name="vauthors"><space/></arg><arg name="title"><space/>MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial<space/></arg><arg name="journal"><space/>Lancet<space/></arg><arg name="volume"><space/>360<space/></arg><arg name="issue"><space/>9326<space/></arg><arg name="pages"><space/>7–22<space/></arg><arg name="date"><space/>July 2002<space/></arg><arg name="pmid"><space/>12114036<space/></arg><arg name="doi"><space/>10.1016/S0140-6736(02)09327-3<space/></arg></template></extension><space/>and in men without cardiovascular disease, there is benefit from lowering abnormally high cholesterol levels (&quot;primary prevention&quot;).<extension extension_name='ref' name="pmid7566020"><template><target>cite journal</target><arg name="vauthors"><space/>Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ<space/></arg><arg name="title"><space/>Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group<space/></arg><arg name="journal"><space/>N. Engl. J. Med.<space/></arg><arg name="volume"><space/>333<space/></arg><arg name="issue"><space/>20<space/></arg><arg name="pages"><space/>1301–7<space/></arg><arg name="date"><space/>November 1995<space/></arg><arg name="pmid"><space/>7566020<space/></arg><arg name="doi"><space/>10.1056/NEJM199511163332001<space/></arg></template></extension><space/>Primary prevention in women was originally practiced only by extension of the findings in studies on men,<extension extension_name='ref' name="pmid17494017"><template><target>cite journal</target><arg name="vauthors"><space/>Grundy SM<space/></arg><arg name="title"><space/>Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes<space/></arg><arg name="journal"><space/>BMJ<space/></arg><arg name="volume"><space/>334<space/></arg><arg name="issue"><space/>7601<space/></arg><arg name="pages"><space/>982–982<space/></arg><arg name="date"><space/>May 2007<space/></arg><arg name="pmid"><space/>17494017<space/></arg><arg name="pmc"><space/>1867899<space/></arg><arg name="doi"><space/>10.1136/bmj.39202.399942.AD<space/></arg></template></extension><space/>since, in women, none of the large statin trials conducted prior to 2007 demonstrated a statistically significant reduction in overall mortality or in cardiovascular endpoints.<extension extension_name='ref' name="pmid17494018"><template><target>cite journal</target><arg name="vauthors"><space/>Kendrick M<space/></arg><arg name="title"><space/>Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? No<space/></arg><arg name="journal"><space/>BMJ<space/></arg><arg name="volume"><space/>334<space/></arg><arg name="issue"><space/>7601<space/></arg><arg name="pages"><space/>983–983<space/></arg><arg name="date"><space/>May 2007<space/></arg><arg name="pmid"><space/>17494018<space/></arg><arg name="pmc"><space/>1867901<space/></arg><arg name="doi"><space/>10.1136/bmj.39202.397488.AD<space/></arg></template></extension><space/>In 2008, a large clinical trial reported that, in apparently healthy adults with increased levels of the inflammatory biomarker high-sensitivity C-reactive protein but with low initial LDL, 20&amp;nbsp;mg/day of rosuvastatin for 1.9 years resulted in a 44% reduction in the incidence of cardiovascular events and a 20% reduction in all-cause mortality; the effect was statistically significant for both genders.<extension extension_name='ref'><template><target>cite journal</target><arg name="title">Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein</arg><arg name="author"><space/>JUPITER Study Group</arg><arg name="journal">N Engl J Med</arg><arg name="year">2008</arg><arg name="doi">10.1056/nejmoa0807646<space/></arg></template></extension><space/>Though this result was met with some skepticism, later studies and meta-analyses likewise demonstrated statistically significant (but smaller) reductions in all-cause and cardiovascular mortality, without significant heterogeneity by gender.<extension extension_name='ref'><template><target>cite journal</target><arg name="vauthors"><space/>Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW<space/></arg><arg name="title"><space/>The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials<space/></arg><arg name="journal"><space/>BMJ<space/></arg><arg name="volume"><space/>338<space/></arg><arg name="pages"><space/>b2376<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/>19567909<space/></arg><arg name="pmc"><space/>2714690<space/></arg><arg name="doi"><space/>10.1136/bmj.b2376<space/></arg></template></extension></paragraph><table class="wikitable" border="1" style="float:right"><tablerow><tablecell bgcolor="#cccccc"><bold>Level</bold><space/><link><target>Milligram</target><part>mg</part></link>/<link><target>Decilitre</target><part>dL</part></link></tablecell><tablecell bgcolor="#cccccc"><bold>Level</bold><space/><link><target>Mole (unit)</target><part>mmol</part></link>/<link><target>Litre</target><part>L</part></link></tablecell><tablecell bgcolor="#cccccc"><bold>Interpretation</bold></tablecell></tablerow><tablerow><tablecell>&lt; 200</tablecell><tablecell>&lt; 5.2</tablecell><tablecell>Desirable level corresponding to lower risk for heart disease</tablecell></tablerow><tablerow><tablecell>200240</tablecell><tablecell>5.26.2</tablecell><tablecell>Borderline high risk</tablecell></tablerow><tablerow><tablecell>&gt; 240</tablecell><tablecell>&gt; 6.2</tablecell><tablecell>High risk</tablecell></tablerow></table><paragraph>The 1987 report of<space/><link><target>National Cholesterol Education Program</target></link>, Adult Treatment Panels suggests the total blood cholesterol level should be: &lt; 200&amp;nbsp;mg/dL normal blood cholesterol, 200239&amp;nbsp;mg/dL borderline-high, &gt; 240&amp;nbsp;mg/dL high cholesterol.<extension extension_name='ref' name="pmid3422148"><template><target>cite journal</target><arg name="vauthors"><space/>,<space/></arg><arg name="title"><space/>Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel<space/></arg><arg name="journal"><space/>Arch. Intern. Med.<space/></arg><arg name="volume"><space/>148<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>36–69<space/></arg><arg name="date"><space/>January 1988<space/></arg><arg name="pmid"><space/>3422148<space/></arg><arg name="doi"><space/>10.1001/archinte.148.1.36<space/></arg></template></extension><space/>The<space/><link><target>American Heart Association</target></link><space/>provides a similar set of guidelines for total (fasting) blood cholesterol levels and risk for heart disease:<extension extension_name='ref' name="urlCholesterol"><template><target>cite web</target><arg name="url"><space/>http://www.americanheart.org/cholesterol/about.jsp<space/></arg><arg name="title"><space/>Cholesterol<space/></arg><arg name="date"><space/>17 November 2008</arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="publisher"><space/>American Heart Association<space/></arg><arg name="accessdate"><space/>2009-02-21</arg></template></extension></paragraph><paragraph>However, as today's testing methods determine LDL (&quot;bad&quot;) and HDL (&quot;good&quot;) cholesterol separately, this simplistic view has become somewhat outdated. The desirable LDL level is considered to be less than 100&amp;nbsp;mg/dL (2.6<space/><link><target>Mole (unit)</target><part>mmol</part></link>/L),<extension extension_name='ref' name="AHA"><link type='external' href='http://www.americanheart.org/cholesterol/about.jsp'>&quot;About cholesterol&quot;</link><space/>American Heart Association</extension><space/>although a newer upper limit of 70&amp;nbsp;mg/dL (1.8&amp;nbsp;mmol/L) can be considered in higher-risk individuals based on some of the above-mentioned trials. A ratio of total cholesterol to HDLanother useful measureof far less than 5:1 is thought to be healthier.</paragraph><paragraph><link><target>File:Blood values sorted by mass and molar concentration.png</target><part>thumb</part><part>center</part><part>600px</part><part><link><target>Reference ranges for blood tests</target></link>, showing usual, as well as optimal, levels of HDL, LDL and total cholesterol in mass and molar concentrations, is found in orange color at right, that is, among the blood constituents with the highest concentration.</part></link></paragraph><paragraph>Total cholesterol is defined as the sum of HDL, LDL, and VLDL. Usually, only the total, HDL, and triglycerides are measured. For cost reasons, the VLDL is usually estimated as one-fifth of the triglycerides and the LDL is estimated using the Friedewald formula (or a<space/><link><target>LDL#Measurement of LDL</target><part>variant</part></link>): estimated LDL = [total cholesterol] [total HDL] [estimated VLDL]. VLDL can be calculated by dividing total triglycerides by five. Direct LDL measures are used when triglycerides exceed 400&amp;nbsp;mg/dL. The estimated VLDL and LDL have more error when triglycerides are above 400&amp;nbsp;mg/dL.<extension extension_name='ref' name="pmid2297909"><template><target>cite journal</target><arg name="vauthors"><space/>Warnick GR, Knopp RH, Fitzpatrick V, Branson L<space/></arg><arg name="title"><space/>Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints<space/></arg><arg name="journal"><space/>Clin. Chem.<space/></arg><arg name="volume"><space/>36<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>15–9<space/></arg><arg name="date"><space/>January 1990<space/></arg><arg name="pmid"><space/>2297909<space/></arg><arg name="doi"><space/></arg></template></extension></paragraph><paragraph>Given the well-recognized role of cholesterol in cardiovascular disease, some studies have shown an inverse correlation between cholesterol levels and mortality. A 2009 study of patients with acute coronary syndromes found an association of hypercholesterolemia with better mortality outcomes.<extension extension_name='ref' name="pmid19645040"><template><target>cite journal</target><arg name="vauthors"><space/>Wang TY, Newby LK, Chen AY, Mulgund J, Roe MT, Sonel AF, Bhatt DL, DeLong ER, Ohman EM, Gibler WB, Peterson ED<space/></arg><arg name="title"><space/>Hypercholesterolemia paradox in relation to mortality in acute coronary syndrome<space/></arg><arg name="journal"><space/>Clin Cardiol<space/></arg><arg name="volume"><space/>32<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>E22–8<space/></arg><arg name="date"><space/>September 2009<space/></arg><arg name="pmid"><space/>19645040<space/></arg><arg name="doi"><space/>10.1002/clc.20518<space/></arg></template></extension><space/>In the<space/><link><target>Framingham Heart Study</target></link>, in subjects over 50 years of age, they found an 11% increase overall and 14% increase in cardiovascular disease mortality per 1&amp;nbsp;mg/dL per year drop in total cholesterol levels. The researchers attributed this phenomenon to the fact that people with severe chronic diseases or cancer tend to have below-normal cholesterol levels.<extension extension_name='ref' name="pmid3560398"><template><target>cite journal</target><arg name="vauthors"><space/>Anderson KM, Castelli WP, Levy D<space/></arg><arg name="title"><space/>Cholesterol and mortality. 30 years of follow-up from the Framingham study<space/></arg><arg name="journal"><space/>JAMA<space/></arg><arg name="volume"><space/>257<space/></arg><arg name="issue"><space/>16<space/></arg><arg name="pages"><space/>2176–80<space/></arg><arg name="date"><space/>April 1987<space/></arg><arg name="pmid"><space/>3560398<space/></arg><arg name="doi"><space/>10.1001/jama.257.16.2176<space/></arg></template></extension><space/>This explanation is not supported by the Vorarlberg Health Monitoring and Promotion Programme, in which men of all ages and women over 50 with very low cholesterol were likely to die of cancer, liver diseases, and mental diseases. This result indicates the low-cholesterol effect occurs even among younger respondents, contradicting the previous assessment among cohorts of older people that this is a proxy or marker for frailty occurring with age.<extension extension_name='ref' name="pmid15006277"><template><target>cite journal</target><arg name="vauthors"><space/>Ulmer H, Kelleher C, Diem G, Concin H<space/></arg><arg name="title"><space/>Why Eve is not Adam: prospective follow-up in 149650 women and men of cholesterol and other risk factors related to cardiovascular and all-cause mortality<space/></arg><arg name="journal"><space/>J Women's Health (Larchmt)<space/></arg><arg name="volume"><space/>13<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>41–53<space/></arg><arg name="year"><space/>2004<space/></arg><arg name="pmid"><space/>15006277<space/></arg><arg name="doi"><space/>10.1089/154099904322836447<space/></arg></template></extension></paragraph><paragraph>The vast majority of doctors and medical scientists consider that there is a link between cholesterol and atherosclerosis as discussed above;<extension extension_name='ref' name="isbn0-12-373979-9"><template><target>cite book</target><arg name="author"><space/>Daniel Steinberg<space/></arg><arg name="title"><space/>The Cholesterol Wars: The Cholesterol Skeptics vs the Preponderance of Evidence<space/></arg><arg name="edition"><space/></arg><arg name="publisher"><space/>Academic Press<space/></arg><arg name="location"><space/>Boston<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="isbn"><space/>0-12-373979-9<space/></arg></template></extension><space/>a small group of scientists, united in<space/><link><target>The International Network of Cholesterol Skeptics</target></link>, questions the link.<extension extension_name='ref'><template><target>cite book</target><arg name="author">Uffe Ravnskov<space/></arg><arg name="title"><space/>The Cholesterol Myths : Exposing the Fallacy that Saturated Fat and Cholesterol Cause Heart Disease<space/></arg><arg name="publisher"><space/>New Trends Publishing, Incorporated<space/></arg><arg name="location"><space/></arg><arg name="year"><space/>2000<space/></arg><arg name="pages"><space/></arg><arg name="isbn"><space/>0-9670897-0-0<space/></arg></template></extension><space/>A 2014 meta analysis which followed over 500,000 patients, concluded there is insufficient evidence to support the recommendation of high consumption of polyunsaturated fatty acids and low consumption of total saturated fats for cardiovascular health.<extension extension_name='ref'><template><target>cite journal</target><arg name="vauthors"><space/>Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, Franco OH, Butterworth AS, Forouhi NG, Thompson SG, Khaw KT, Mozaffarian D, Danesh J, Di Angelantonio E<space/></arg><arg name="title"><space/>Association of dietary, circulating, and supplement fatty acids with coronary risk: A systematic review and meta-analysis<space/></arg><arg name="journal"><space/>Annals of internal medicine<space/></arg><arg name="volume"><space/>160<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>398–406<space/></arg><arg name="year"><space/>2014<space/></arg><arg name="pmid"><space/>24723079<space/></arg><arg name="doi"><space/>10.7326/M13-1788<space/></arg></template></extension></paragraph><heading level='3'>Hypocholesterolemia</heading><paragraph>Abnormally low levels of cholesterol are termed<space/><italics><link><target>hypocholesterolemia</target></link></italics>. Research into the causes of this state is relatively limited, but some studies suggest a link with<space/><link><target>depression (mood)</target><part>depression</part></link>,<space/><link><target>cancer</target></link>, and<space/><link><target>cerebral hemorrhage</target></link>. In general, the low cholesterol levels seem to be a consequence, rather than a cause, of an underlying illness.<extension extension_name='ref' name="pmid18061058"></extension><space/>A genetic defect in cholesterol synthesis causes<space/><link><target>Smith-Lemli-Opitz syndrome</target></link>, which is often associated with low plasma cholesterol levels. Hyperthyroidism, or any other endocrine disturbance which causes upregulation of the<space/><link><target>LDL receptor</target></link><space/>may result in hypocholesterolaemia.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Rizos</arg><arg name="first1">C.V.</arg><arg name="title">Effects of Thyroid Dysfunction on Lipid Profile</arg><arg name="journal">The Open Cardiovascular Medicine Journal</arg><arg name="date">24 February 2011</arg><arg name="volume">5</arg><arg name="issue">1</arg><arg name="pages">76–84</arg><arg name="doi">10.2174/1874192401105010076</arg></template></extension></paragraph><heading level='3'>Cholesterol testing</heading><paragraph>The<space/><link><target>American Heart Association</target></link><space/>recommends testing cholesterol every five years for people aged 20 years or older.<extension extension_name='ref' name="urlHow To Get Your Cholesterol Tested"><template><target>cite web</target><arg name="url"><space/>http://www.heart.org/HEARTORG/Conditions/Cholesterol/SymptomsDiagnosisMonitoringofHighCholesterol/How-To-Get-Your-Cholesterol-Tested_UCM_305595_Article.jsp<space/></arg><arg name="title"><space/>How To Get Your Cholesterol Tested<space/></arg><arg name="author"><space/></arg><arg name="authorlink"><space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="publisher"><space/>American Heart Association<space/></arg><arg name="pages"><space/></arg><arg name="archiveurl"><space/></arg><arg name="archivedate"><space/></arg><arg name="quote"><space/></arg><arg name="accessdate"><space/>2013-07-10</arg></template></extension><space/>A separate set of<space/><link><target>American Heart Association</target></link><space/>guidelines issued in 2013 indicates that patients taking<space/><link><target>statin</target></link><space/>medications should have their cholesterol tested 412 weeks after their first dose and then every 312 months thereafter.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.cardiosource.org/News-Media/Publications/Cardiology-Magazine/2013/12/Getting-a-Grasp-of-the-Guidelines.aspx</arg><arg name="publisher">American College of Cardiology</arg><arg name="authors">Stone NJ, Robinson J, Goff DC, Jr</arg><arg name="year">2013</arg><arg name="title">Getting a grasp of the Guidelines</arg><arg name="accessdate">2 April 2014</arg></template></extension></paragraph><paragraph>A blood sample after 12-hour fasting is taken by a doctor, or a home cholesterol-monitoring device is used to determine a<space/><link><target>lipid profile</target><part>lipoprotein profile</part></link>. This measures total cholesterol, LDL (bad) cholesterol, HDL (good) cholesterol, and triglycerides. It is recommended to test cholesterol at least every five years if a person has total cholesterol of 5.2&amp;nbsp;mmol/L or more (200+&amp;nbsp;mg/dL), or if a man over age 45 or a woman over age 50 has HDL (good) cholesterol less than 1&amp;nbsp;mmol/L (40&amp;nbsp;mg/dL), or there are other risk factors for heart disease and stroke. Other risk factors for heart disease include Diabetes, Hypertension (or use of anti-hypertensive medications), low HDL, family history of CAD and hypercholesterolemia, and cigarette smoking.<extension extension_name='ref' name="urlATP III Update 2004"><template><target>cite web</target><arg name="url"><space/>http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3upd04.htm<space/></arg><arg name="title"><space/>Implications of Recent Clinical Trials for the ATP III Guidelines<space/></arg><arg name="author"><space/></arg><arg name="authorlink"><space/></arg><arg name="work"><space/></arg><arg name="publisher"><space/>National Heart, Lungs and Blood Institute<space/></arg><arg name="pages"><space/></arg><arg name="archiveurl"><space/></arg><arg name="archivedate"><space/></arg><arg name="quote"><space/></arg><arg name="accessdate"><space/>2014-01-27</arg></template></extension></paragraph><heading level='2'>Interactive pathway map</heading><paragraph><template><target>StatinPathway WP430</target><arg name="highlight">Cholesterol</arg></template></paragraph><heading level='2'>Cholesteric liquid crystals</heading><paragraph>Some cholesterol derivatives (among other simple cholesteric lipids) are known to generate the<space/><link><target>liquid crystal</target><trail>line</trail></link><space/>&quot;cholesteric phase&quot;. The cholesteric phase is, in fact, a<space/><link><target>chirality (chemistry)</target><part>chiral</part></link><space/><link><target>Liquid crystal</target><part>nematic phase</part></link>, and it changes colour when its temperature changes. This makes cholesterol derivatives useful for indicating temperature in<space/><link><target>liquid crystal display</target></link><space/><link><target>thermometer</target><trail>s</trail></link><space/>and in temperature-sensitive paints.</paragraph><heading level='2'>Stereoisomers</heading><paragraph>Cholesterol has 256<space/><link><target>stereoisomers</target></link><space/>that arise from its 8 stereocenters, although only two of the stereoisomers are of biochemical significance (<italics>nat</italics>-cholesterol and<space/><italics>ent</italics>-cholesterol, for<space/><italics>natural</italics><space/>and<space/><italics>enantiomer</italics>, respectively),<extension extension_name='ref' name="pmid14530278"><template><target>cite journal</target><arg name="vauthors"><space/>Westover EJ, Covey DF, Brockman HL, Brown RE, Pike LJ<space/></arg><arg name="title"><space/>Cholesterol depletion results in site-specific increases in epidermal growth factor receptor phosphorylation due to membrane level effects. Studies with cholesterol enantiomers<space/></arg><arg name="journal"><space/>J. Biol. Chem.<space/></arg><arg name="volume"><space/>278<space/></arg><arg name="issue"><space/>51<space/></arg><arg name="pages"><space/>51125–33<space/></arg><arg name="date"><space/>December 2003<space/></arg><arg name="pmid"><space/>14530278<space/></arg><arg name="pmc"><space/>2593805<space/></arg><arg name="doi"><space/>10.1074/jbc.M304332200<space/></arg></template></extension><extension extension_name='ref' name="pmid22869373"><template><target>cite journal</target><arg name="vauthors"><space/>Kristiana I, Luu W, Stevenson J, Cartland S, Jessup W, Belani JD, Rychnovsky SD, Brown AJ<space/></arg><arg name="title"><space/>Cholesterol through the looking glass: ability of its enantiomer also to elicit homeostatic responses<space/></arg><arg name="journal"><space/>J. Biol. Chem.<space/></arg><arg name="volume"><space/>287<space/></arg><arg name="issue"><space/>40<space/></arg><arg name="pages"><space/>33897–904<space/></arg><arg name="date"><space/>September 2012<space/></arg><arg name="pmid"><space/>22869373<space/></arg><arg name="pmc"><space/>3460484<space/></arg><arg name="doi"><space/>10.1074/jbc.M112.360537<space/></arg></template></extension><space/>and only one occurs naturally (<italics>nat</italics>-cholesterol).</paragraph><paragraph><link><target>File:Nat-cholesterol and ent-cholesterol.jpg</target><part>300px</part></link></paragraph><heading level='2'>See also</heading><list type='bullet'><listitem><link><target>Arcus senilis</target></link><space/>&quot;Cholesterol ring&quot; in the eyes</listitem><listitem><link><target>Cholesterol embolism</target></link></listitem><listitem><link><target>Cholesterol total synthesis</target></link></listitem><listitem><link><target>Diet and heart disease</target></link></listitem><listitem><link><target>Familial hypercholesterolaemia</target></link></listitem><listitem><link><target>List of cholesterol in foods</target></link></listitem><listitem><link><target>NiemannPick disease</target></link><space/>Type C</listitem><listitem><link><target>Oxycholesterol</target></link></listitem><listitem><link><target>Vertical Auto Profile</target></link></listitem></list><heading level='2'>Additional images</heading><paragraph><table style='border-collapse: collapse; border: 1px solid grey;'><tablerow><tablecell valign="top" align="left"><link><target>File:Steroidogenesis.svg</target><part>thumb</part><part>center</part><part></part></link><xhtml:br></xhtml:br><link><target>Steroidogenesis</target></link>, using cholesterol as building material</tablecell><tablecell valign="top" align="left"><link><target>Image:Cholesterol_Spacefill.jpeg</target><part>thumb</part><part>center</part><part></part></link><xhtml:br></xhtml:br><link><target>Space-filling model</target></link><space/>of the Cholesterol molecule</tablecell><tablecell valign="top" align="left"><link><target>Image:Trimethyl_steroid-nomenclature.png</target><part>thumb</part><part>center</part><part></part></link><xhtml:br></xhtml:br>Numbering of the<space/><link><target>steroid</target></link><space/>nuclei</tablecell></tablerow></table></paragraph><heading level='2'>References</heading><paragraph><template><target>Reflist</target><arg>35em</arg></template></paragraph><heading level='2'>External links</heading><list type='bullet'><listitem><link type='external' href='http://gmd.mpimp-golm.mpg.de/Spectrums/EC32F379-6956-4750-B41A-F063F3DD480E.aspx'>GMD MS Spectrum</link></listitem><listitem><link type='external' href='http://www.nhlbi.nih.gov/guidelines/cholesterol/'>Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults</link><space/>US National Institutes of Health Adult Treatment Panel III</listitem><listitem><link type='external' href='http://www.heart.org/HEARTORG/Conditions/Cholesterol/AboutCholesterol/About-Cholesterol_UCM_001220_Article.jsp'>American Heart Association</link><space/>&quot;About Cholesterol&quot;</listitem><listitem>Cholesterol at<space/><link type='external' href='http://labtestsonline.org/understanding/analytes/cholesterol/tab/test'>Lab Tests Online</link></listitem><listitem><link type='external' href='http://www.radcliffecardiology.com/prevention-risk/cholestestrol'>Cholestestrol</link></listitem></list><paragraph><template><target>Sterols</target></template><template><target>Cholesterol and steroid intermediates</target></template><template><target>Vascular diseases</target></template><template><target>Androgenics</target></template></paragraph><paragraph><template><target>Authority control</target></template></paragraph><paragraph><link><target>Category:GABAA receptor positive allosteric modulators</target></link><link><target>Category:Lipid disorders</target></link><link><target>Category:Neurosteroids</target></link><link><target>Category:Nutrition</target></link><link><target>Category:Steroids</target></link><link><target>Category:Sterols</target></link></paragraph></article>